Neuropace Inc (NPCE) Stock Price, Quote & News

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data m...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 237 2700

Fax: 650 237 2701

Website: www.neuropace.com

Address:

455 North Bernardo Avenue, Mountain View, United States

erevnon Dec. 16 at 3:31 PM

UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 16 at 2:27 PM

UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.

0 · Reply

JarvisFlow Dec. 10 at 4:00 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.

0 · Reply

SuperGreenToday Dec. 9 at 9:37 PM

$NPCE Share Price: $16.26 Contract Selected: May 15, 2026 $17.5 Calls Buy Zone: $0.73 – $0.90 Target Zone: $1.36 – $1.66 Potential Upside: 76% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

stockwitsuser2449 Dec. 1 at 12:35 PM

$NPCE

0 · Reply

stockwitsuser2449 Nov. 20 at 7:07 PM

$NPCE large drop here

1 · Reply

HypnoTrader Nov. 19 at 6:48 PM

$NPCE no way to confirm anything an anonymous account is telling you, but the chart seems to agree....

1 · Reply

HypnoTrader Nov. 19 at 6:46 PM

$NPCE

0 · Reply

johnemac Nov. 19 at 6:45 PM

$NPCE In a sample size of one my son continues to be seizure-free since February and his RNS (NPCE's main product) surgery. In addition he is able now to wean back his meds considerably. Thank you Neuropace.

0 · Reply

Scoops1212 Nov. 19 at 3:01 PM

$NPCE If you believe in the treatment, this is the time to go big. The numbers show this should be at $40, and is at $13. I’m not a pumper, and know how to crunch these numbers. This should be at $40 right now!

0 · Reply

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

Dec 8, 2025, 8:00 AM EST - 17 days ago

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Dec 2, 2025, 8:01 AM EST - 23 days ago

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Nov 24, 2025, 8:00 AM EST - 4 weeks ago

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

Nov 4, 2025, 11:06 PM EST - 7 weeks ago

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 7 weeks ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 22, 2025, 8:00 AM EDT - 2 months ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Aug 28, 2025, 8:00 AM EDT - 4 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 12, 2025, 9:50 PM EDT - 4 months ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 1, 2025, 7:30 AM EDT - 5 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Jun 24, 2025, 4:05 PM EDT - 6 months ago

NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 3:42 AM EDT - 6 months ago

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Jun 13, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Jun 11, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Jun 6, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

Jun 4, 2025, 4:09 PM EDT - 7 months ago

NeuroPace Secures Up to $75 Million in Debt Financing

Jun 3, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Jun 2, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

Jun 1, 2025, 10:00 AM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 12:45 PM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

May 27, 2025, 12:48 PM EDT - 7 months ago

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

May 27, 2025, 8:00 AM EDT - 7 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 13, 2025, 10:33 PM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 8 months ago

NeuroPace Reports First Quarter 2025 Financial Results

Apr 14, 2025, 4:05 PM EDT - 9 months ago

NeuroPace Provides Update on Tariff Status

Apr 8, 2025, 8:00 AM EDT - 9 months ago

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Apr 3, 2025, 8:00 AM EDT - 9 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Apr 2, 2025, 4:05 PM EDT - 9 months ago

NeuroPace Announces Refocusing of Product Portfolio

Mar 26, 2025, 8:00 AM EDT - 9 months ago

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 4, 2025, 7:45 PM EST - 10 months ago

NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 10 months ago

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

erevnon Dec. 16 at 3:31 PM

UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 16 at 2:27 PM

UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.

0 · Reply

JarvisFlow Dec. 10 at 4:00 PM

JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.

0 · Reply

SuperGreenToday Dec. 9 at 9:37 PM

0 · Reply

stockwitsuser2449 Dec. 1 at 12:35 PM

$NPCE

0 · Reply

stockwitsuser2449 Nov. 20 at 7:07 PM

$NPCE large drop here

1 · Reply

HypnoTrader Nov. 19 at 6:48 PM

$NPCE no way to confirm anything an anonymous account is telling you, but the chart seems to agree....

1 · Reply

HypnoTrader Nov. 19 at 6:46 PM

$NPCE

0 · Reply

johnemac Nov. 19 at 6:45 PM

0 · Reply

Scoops1212 Nov. 19 at 3:01 PM

0 · Reply

BEATOFtheMARKET Nov. 17 at 10:54 AM

$NOG $NPCE $NRDS $NRT $NTCT

0 · Reply

stockwitsuser2449 Nov. 15 at 6:01 PM

$NPCE 15 strike put options working out so far

0 · Reply

Scoops1212 Nov. 12 at 2:05 PM

$NPCE The big question is what does this company have to do financially, to beat their opening price over 4 years ago? They’ve had strong quarterly’s all but once, and they had never reached $20. What da?!

0 · Reply